

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 19, 2004, 16:34:27 ; Search time 19.3191 Seconds
(without alignments)
74.274 Million cell updates/sec

Title: US-09-830-954A-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_23Sep04:
1: geneseqp1980s:
2: geneseqp1990s:
3: geneseqp2000s:
4: geneseqp2001s:
5: geneseqp2002s:
6: geneseqp2003as:
7: geneseqp2003bs:
8: geneseqp2004s:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

Result No.	Query Score	Match	Length	DB	ID	Description
1	24	100.0	4	2	AAW70870	Aaw70870 Beta-amyl
2	24	100.0	4	6	AAO16062	Aao16062 Neurologi
3	24	100.0	4	6	ABP70744	Abp70744 Antigenic
4	24	100.0	4	7	ADB75167	Adb75167 Human amy
5	24	100.0	4	7	ADE36574	Ade36574 Beta-amyl
6	24	100.0	4	8	ADJ88108	Adj88108 Human bet
7	24	100.0	4	8	ADJ71364	Adj71364 N-termina
8	24	100.0	4	8	ADJ71377	Adj71377 N-termina
9	24	100.0	4	8	ADP90808	Adp90808 Protein/p

10	24	100.0	5	6	ADA90172	Ada90172 Anti-Abet
11	24	100.0	5	8	ADJ71378	Adj71378 N-termina
12	24	100.0	5	8	ADJ71365	Adj71365 N-termina
13	24	100.0	5	8	ADJ71352	Adj71352 N-termina
14	24	100.0	6	2	AAW70868	Aaw70868 Beta-amyl
15	24	100.0	6	4	AAB47109	Aab47109 Epitope #
16	24	100.0	6	6	AAO16067	Aao16067 Neurologi
17	24	100.0	6	6	ADA90170	Ada90170 Anti-Abet
18	24	100.0	6	7	ADB75165	Adb75165 Human amy
19	24	100.0	6	8	ADJ88114	Adj88114 fd phage
20	24	100.0	6	8	ADJ71366	Adj71366 N-termina
21	24	100.0	6	8	ADJ71379	Adj71379 N-termina
22	24	100.0	6	8	ADJ71340	Adj71340 N-termina
23	24	100.0	6	8	ADJ71353	Adj71353 N-termina
24	24	100.0	6	8	ADK52251	Adk52251 Human amy
25	24	100.0	6	8	ADK52264	Adk52264 Guinea pi
26	24	100.0	6	8	ADK52261	Adk52261 Rabbit am
27	24	100.0	6	8	ADK52260	Adk52260 Primate a
28	24	100.0	6	8	ADK52266	Adk52266 Amyloid b
29	24	100.0	7	4	AAB46202	Aab46202 Human APP
30	24	100.0	7	5	AAO14421	Aao14421 Synthetic
31	24	100.0	7	6	AAO19884	Aao19884 Human amy
32	24	100.0	7	6	AAE35432	Aae35432 Abeta pep
33	24	100.0	7	6	ADA90925	Ada90925 Solid-pha
34	24	100.0	7	6	ADA90142	Ada90142 Anti-Abet
35	24	100.0	7	6	ADA90141	Ada90141 Anti-Abet
36	24	100.0	7	6	ADA90924	Ada90924 Solid-pha
37	24	100.0	7	6	ADA90171	Ada90171 Anti-Abet
38	24	100.0	7	8	ADJ71565	Adj71565 N-termina
39	24	100.0	7	8	ADJ71380	Adj71380 N-termina
40	24	100.0	7	8	ADJ71341	Adj71341 N-termina
41	24	100.0	7	8	ADJ71367	Adj71367 N-termina
42	24	100.0	7	8	ADJ71354	Adj71354 N-termina
43	24	100.0	8	2	AAW70865	Aaw70865 Beta-amyl
44	24	100.0	8	5	AAU78518	Aau78518 N terminu
45	24	100.0	8	6	ABP70740	Abp70740 Antigenic

ALIGNMENTS

RESULT 1
 AAW70870
 ID AAW70870 standard; peptide; 4 AA.
 XX
 AC AAW70870;
 XX
 DT 04-FEB-1999 (first entry)
 XX
 DE Beta-amyloid peptide epitope.
 XX
 KW Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
 KW amyloid deposit; Alzheimer's disease.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX

PN WO9844955-A1.
XX
PD 15-OCT-1998.
XX
PF 09-APR-1998; 98WO-US006900.
XX
PR 09-APR-1997; 97US-0041850P.
XX
PA (MIND-) MINDSET LTD.
PA (MCIN/) MCINNIS P A.
XX
PI Chain DG;
XX
DR WPI; 1998-594476/50.
XX
PT Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT use of recombinant DNA encoding an antibody specific for the N- or C-
PT terminus of an amyloid-beta peptide.
XX
PS Example 1; Page 47; 58pp; English.
XX
CC The present sequence represents a peptide epitope derived from beta-
CC amyloid precursor protein peptide. The specification describes a method
CC for prevention or inhibition of progression of Alzheimer's disease. The
CC method comprises administering a composition comprising a recombinant DNA
CC molecule containing a gene encoding a recombinant antibody end-specific
CC for the N-terminus or the C-terminus of an amyloid-beta peptide, operably
CC linked to a promoter which is expressed in the central nervous system.
CC The recombinant antibody molecules prevent the accumulation of beta-
CC amyloid peptides in the extracellular space, interstitial fluid and
CC cerebrospinal fluid and the aggregation of such peptides into amyloid
CC deposits in the brain. They also inhibit the progression of Alzheimer's
CC disease by inhibiting the interaction of beta-amyloid peptides mediating
CC Alzheimer's disease induced neurotoxicity and inhibiting the Alzheimer's
CC disease induced complement activation and cytokine release involved in
CC the inflammatory process
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 2; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 2
AAO16062
ID AAO16062 standard; peptide; 4 AA.
XX
AC AAO16062;
XX
DT 27-FEB-2003 (first entry)
XX
DE Neurological/CNS disease treatment method-related peptide #1.

XX
KW Vaccine; gene therapy; neurological disease; CNS disorder;
KW central nervous system disorder; olfactory system; Alzheimer's disease;
KW Creutzfeld-Jakob disease; Huntington's chorea; Parkinson's disease;
KW viral infection of the brain; brain tumour; lysosomal storage disease;
KW multiple sclerosis.
XX
OS Unidentified.
XX
PN WO200274243-A2.
XX
PD 26-SEP-2002.
XX
PF 15-MAR-2002; 2002WO-US008042.
XX
PR 15-MAR-2001; 2001US-00808037.
XX
PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
PA (MCIN/) MCINNIS P.
XX
PI Solomon B, Frenkel D;
XX
DR WPI; 2003-040542/03.
XX
PT Treating or diagnosing neurological diseases of the central nervous
PT system, e.g. Alzheimer's disease, comprises displaying a polypeptide or
PT diagnostic agent on viral display vehicle and introducing or detecting
PT the display vehicle.
XX
PS Example 9; Page 138; 214pp; English.
XX
CC The invention comprises a method for treating a neurological disease or a
CC central nervous system (CNS) disorder. The method involves displaying a
CC therapeutic molecule capable of treating the neurological disease or CNS
CC disorder on a viral display vehicle. The viral display vehicle is then
CC introduced into the olfactory system of a subject to treat the disease or
CC disorder. The method of the invention is useful for preventing, treating
CC and diagnosing neurological diseases or CNS disorders, such as:
CC Alzheimer's disease; Creutzfeld-Jakob disease; Huntington's chorea; viral
CC infections of the brain; brain tumours; lysosomal storage diseases;
CC Parkinson's disease; and multiple sclerosis. The present amino acid
CC sequence represents a peptide which was used in the invention
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 6; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 3
ABP70744
ID ABP70744 standard; peptide; 4 AA.

XX
AC ABP70744;
XX
DT 15-MAY-2003 (first entry)
XX
DE Antigenic peptide, SEQ ID 5.
XX
KW Nootropic; neuroprotective; antiinflammatory; vaccine; antigenic product;
KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW hereditary Icelandic syndrome; senility; multiple myeloma;
KW Creutzfeldt-Jakob disease; Kuru; Gerstmann-Straussler-Scheinker disease;
KW fatal familial insomnia; scrapie; bovine spongiform encephalitis;
KW antigenic; multiantigen.
XX
OS Synthetic.
XX
PN WO2003000719-A2.
XX
PD 03-JAN-2003.
XX
PF 20-JUN-2002; 2002WO-US019567.
XX
PR 20-JUN-2001; 2001US-0299201P.
PR 12-APR-2002; 2002US-0371717P.
XX
PA (UYRA-) UNIV RAMOT.
PA (MCIN/) MCINNIS P.
XX
PI Mcinnis P, Solomon B;
XX
DR WPI; 2003-239139/23.
XX
PT Antigenic product has dendritic polymer built on core molecule having
PT terminal functional groups to which antigenic peptide that has epitope of
PT deposit-forming polypeptide involved in plaque-forming disease is joined.
XX
PS Claim 6; Page 44; 70pp; English.
XX
CC The present invention relates to antigenic products (A), comprising a
CC dendritic polymer built on a core molecule which is at least difunctional
CC to provide branching and containing up to 16 terminal functional groups
CC to which an antigenic peptide, that comprises an epitope of a deposit-
CC forming polypeptide involved in plaque-forming disease, is joined by
CC covalent bonds. The antigenic products are useful for eliciting an immune
CC response against a deposit-forming polypeptide involved in a plaque-
CC forming disease or disorder, e.g. Alzheimer's disease, SAA amyloidosis,
CC hereditary Icelandic syndrome, senility, multiple myeloma, Creutzfeldt-
CC Jakob disease, Kuru, Gerstmann-Straussler-Scheinker disease, fatal
CC familial insomnia, scrapie or bovine spongiform encephalitis, by
CC administering the antigenic product to a subject in need of it. The
CC present sequence is one such antigenic peptide, which was used to
CC illustrate the invention
XX
SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 6; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 4
ADB75167
ID ADB75167 standard; peptide; 4 AA.
XX
AC ADB75167;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human amyloid beta peptide SEQ ID NO:8.
XX
KW antibody; amyloid beta peptide; amyloid beta; nootropic; neuroprotective;
KW antibody therapy; Alzheimer's disease; mild cognitive impairment;
KW cerebral amyloid angiopathy; congophilic angiopathy; Down's syndrome;
KW inclusion body myositis; neurotoxicity; beta amyloid precursor protein;
KW APP; human.
XX
OS Homo sapiens.
XX
PN WO2003074081-A1.
XX
PD 12-SEP-2003.
XX
PF 21-OCT-2002; 2002WO-US031590.
XX
PR 28-FEB-2002; 2002US-00084380.
XX
PA (MIND-) MINDSET BIOPHARMACEUTICALS USA INC.
XX
PI Chain DG;
XX
DR WPI; 2003-731651/69.
XX
PT New antibody that is targeted to amyloid beta peptide, or its fragment,
PT useful for treating a subject having Alzheimer's disease, or a disease or
PT disorder characterized by amyloid beta deposition, e.g. cognitive
PT impairment or dementia.
XX
PS Disclosure; Page 60; 63pp; English.
XX
CC The present invention describes an antibody that is targeted to amyloid
CC beta peptide, or its fragment. Also described: (1) an antibody that is
CC free-end specific and is targeted to: (a) the free N-terminus of amyloid
CC beta-peptide; (b) the free N-terminus of amyloid beta-peptide, where the
CC first amino acid of amyloid beta-peptide is aspartate; (c) the free N-
CC terminus of N- and/or C-terminus-truncated amyloid beta-peptide fragment;
CC (d) the free C-terminus of the amyloid beta-peptide Abeta1-39, Abeta1-40,
CC Abeta1-41 or Abeta1-43; or (e) to the free C-terminus of N- and/or C-
CC terminus-truncated amyloid beta-peptide fragment; (2) a single chain or
CC artificial antibody that is free-end specific and is targeted to the free
CC C-terminus of the amyloid beta-peptide Abeta1-42; and (3) a

CC pharmaceutical composition comprising the antibody, and a carrier. The
CC antibody targeted to amyloid beta peptide has nootropic and
CC neuroprotective activities, and can be used in antibody therapy. The
CC antibody or its fragment is useful for manufacturing a medicament for
CC treating a subject having Alzheimer's disease, or a disease or disorder
CC characterised by amyloid beta deposition (e.g. mild cognitive impairment,
CC cerebral amyloid angiopathy or congophilic angiopathy, Alzheimer's
CC disease associated with Down's syndrome, or inclusion body myositis), or
CC for delaying, inhibiting or suppressing accumulation of amyloid beta
CC peptide, or the neurotoxicity of amyloid beta peptide or its fragment.
CC Amyloid beta peptide are derived from beta amyloid precursor protein
CC (APP). The present sequence represents an amyloid beta peptide which is
CC used in the exemplification of the present invention.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4

||||

Db 1 EFRH 4

RESULT 5

ADE36574

ID ADE36574 standard; peptide; 4 AA.

XX

AC ADE36574;

XX

DT 29-JAN-2004 (first entry)

XX

DE Beta-amyloid (Abeta) peptide 3-6 SEQ ID NO:2.

XX

KW immune response; beta-secretase cleavage site; amyloid precursor protein;
KW APP; nootropic; neuroprotective; vaccine; passive immunisation;
KW Alzheimer's disease.

XX

OS Synthetic.

XX

PN WO2003076455-A2.

XX

PD 18-SEP-2003.

XX

PF 04-MAR-2003; 2003WO-US006388.

XX

PR 05-MAR-2002; 2002US-0361344P.

XX

PA (UYRA-) UNIV RAMOT AT TEL AVIV LTD.

PA (MCIN/) MCINNIS P.

XX

PI Solomon B;

XX

DR WPI; 2003-865017/80.

XX

PT Immunizing composition, useful for treating Alzheimer's disease by

PT inhibiting processing of amyloid precursor protein, also antibodies for
PT passive immunization.

XX

PS Disclosure; SEQ ID NO 2; 76pp; English.

XX

CC The present invention describes an immunising composition (A) comprising:
CC (a) an antigenic product (I) which induces an immune response against the
CC beta-secretase cleavage site of amyloid precursor protein (APP); and (b)
CC a carrier, diluent, excipient, adjuvant or auxiliary. Also described: (1)
CC a molecule (II) comprising the antigen-binding part of an antibody (Ab)
CC directed against the beta-secretase cleavage site of APP; (2) a
CC filamentous bacteriophage (FB) that displays (II), where this is a single
CC -chain Ab, on its surface; and (3) a composition containing FB. (A) has
CC nootropic and neuroprotective activities, and can be used in vaccines or
CC passive immunisation. (A) inhibits the cleavage of APP and so prevents
CC the formation of beta-amyloid. (A) can be used to induce an immune
CC response against the beta-secretase cleavage site of APP, specifically
CC for treatment and prevention of Alzheimer's disease. The molecule (II)
CC that contains the antigen-binding part of an Ab directed against the
CC cleavage site, or a filamentous phage that displays such an Ab (as a
CC single-chain molecule) can be used similarly, for passive immunisation.
CC The present sequence represents a beta-amyloid (Abeta) peptide which is
CC used in the exemplification of the present invention.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 7; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 6

ADJ88108

ID ADJ88108 standard; peptide; 4 AA.

XX

AC ADJ88108;

XX

DT 06-MAY-2004 (first entry)

XX

DE Human beta amyloid peptide anti-aggregating epitope.

XX

KW Neurological disease; central nervous system; CNS disorder;
KW plaque-forming disease; Alzheimer's disease; SAA amyloidosis;
KW hereditary Icelandic syndrome; senility; multiple myeloma; scrapie;
KW bovine spongiform encephalopathy; BSE; kuru; Creutzfeldt-Jakob disease;
KW CJD; Gerstmann-Sträussler-Scheinker disease; GSS; fatal familial insomnia;
KW FFI; non-plaque-forming disease; Huntington's chorea; viral infection;
KW brain tumour; lysosomal storage disease; neurodegeneration;
KW multiple sclerosis; vaccine; beta amyloid peptide; epitope; beta AP;
KW human.

XX

OS Homo sapiens.

XX

PN US2004013647-A1.

XX

PD 22-JAN-2004.

XX

PF 11-MAR-2003; 2003US-00384788.

XX

PR 03-SEP-1999; 99US-0152417P.

PR 29-DEC-1999; 99US-00473653.

PR 31-JUL-2000; 2000US-00629971.

PR 31-AUG-2000; 2000WO-IL000518.

PR 15-MAR-2001; 2001US-00808037.

PR 07-AUG-2001; 2001US-00830954.

PR 12-APR-2002; 2002US-0371735P.

PR 06-JUN-2002; 2002US-00162889.

XX

PA (UYRA-) UNIV RAMOT AT TEL AVIV LTD.

XX

PI Solomon B, Frenkel D;

XX

DR WPI; 2004-108188/11.

XX

PT Treating neurological disease CNS e.g., Alzheimer's disease, by displaying therapeutic molecule capable of treating the disease on viral display vehicle which is then administered to subject through olfactory system.

XX

PS Example 10; SEQ ID NO 1; 68pp; English.

XX

CC The invention relates to a method of treating a neurological disease or disorder of the central nervous system (CNS). The method involves displaying a therapeutic molecule capable of treating the neurological disease or disorder of the CNS on a viral display vehicle and introducing viral display vehicle into a subject by applying an effective amount of the viral display vehicle displaying the therapeutic molecule to an olfactory system of the subject. The method is useful for treating a neurological disease or disorder of CNS such as a plaque-forming disease such as Alzheimer's disease, late onset Alzheimer's disease, presymptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic syndrome, senility, multiple myeloma, scrapie, bovine spongiform encephalopathy (BSE), kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Streussler-Sheinker disease (GSS) or fatal familial insomnia (FFI). The method is also useful for treating a non plaque forming disease or disorder e.g. Huntington's chorea, viral infections of the brain, brain tumours, lysosomal storage diseases which cause neurodegeneration and are manifested by enzyme deficiencies and multiple sclerosis. The invention is also used in the preparation of vaccines. The present sequence is human beta amyloid peptide (beta AP) anti-aggregating epitope. This sequence is used to illustrate the method of the invention.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 EFRH 4

||||

Db 1 EFRH 4

RESULT 7

ADJ71364

ID ADJ71364 standard; peptide; 4 AA.

XX

AC ADJ71364;

XX

DT 06-MAY-2004 (first entry)

XX

DE N-terminal truncated beta-amyloid peptide, SEQ ID 27.

XX

KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX

OS Homo sapiens.

XX

PN WO2004013172-A2.

XX

PD 12-FEB-2004.

XX

PF 18-JUL-2003; 2003WO-EP007833.

XX

PR 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX

PA (INNO-) INNOCYANICS NV.

XX

PI Delacourte A, Sergeant N;

XX

DR WPI; 2004-180423/17.

XX

PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.

XX

PS Claim 4; Page 61; 104pp; English.

XX

CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 8; Length 4;

Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 EFRH 4

||||

Db

1 EFRH 4

RESULT 8

ADJ71377

ID ADJ71377 standard; peptide; 4 AA.

XX

AC ADJ71377;

XX

DT 06-MAY-2004 (first entry)

XX

DE N-terminal truncated beta-amyloid peptide, SEQ ID 40.

XX

KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;

KW amyloid precursor protein; APP; Alzheimer's disease.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "Pyroglutamic acid"

XX

PN WO2004013172-A2.

XX

PD 12-FEB-2004.

XX

PF 18-JUL-2003; 2003WO-EP007833.

XX

PR 24-JUL-2002; 2002EP-00447147.

PR 06-AUG-2002; 2002US-0401497P.

XX

PA (INNO-) INNOGENETICS NV.

XX

PI Delacourte A, Sergeant N;

XX

DR WPI; 2004-180423/17.

XX

PT New beta-amyloid or amyloid precursor protein preparation, useful as a prophylactic vaccine or a therapeutic for preventing or treating a disease associated with beta-amyloid formation and/or aggregation, e.g. Alzheimer's disease.

XX

PS Claim 4; Page 62; 104pp; English.

XX

CC The present invention relates to preparations (I) comprising a beta-amyloid peptide variant or beta-amyloid N-terminal fragment, or N-terminal amyloid precursor protein (APP) soluble fragment or C-terminal fragment. The beta-amyloid or APP preparations are useful for manufacturing a prophylactic vaccine or a therapeutic, or as a prophylactic vaccine for the prevention, or as a therapeutic for the treatment of a disease associated with beta-amyloid formation and/or aggregation, such as Alzheimer's disease.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches	4;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	1	EFRH	4						
Db	1	EFRH	4						

RESULT 9
ADP90808
ID ADP90808 standard; peptide; 4 AA.
XX
AC ADP90808;
XX
DT 09-SEP-2004 (first entry)
XX
DE Protein/peptide labelling method-related affinity tag peptide #3.
XX
KW protein labelling; peptide labelling;
KW irreversible affinity tagging residue;
KW reversible affinity tagging residue; high throughput screening assay;
KW pharmaceutical agent; affinity tag.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Modified-site 4
FT /note= "C-terminal amide"
XX
PN WO2004051270-A2.
XX
PD 17-JUN-2004.
XX
PF 04-DEC-2003; 2003WO-EP013715.
XX
PR 05-DEC-2002; 2002GB-00028429.
XX
PA (NOVS) NOVARTIS AG.
PA (NOVS) NOVARTIS PHARMA GMBH.
XX
PI Auer M, Meisner N, Seifert J;
XX
DR WPI; 2004-480677/45.
XX
PT Providing labeled target protein or target peptide by contacting chemical
PT compound with affinity support, removing impurities in reaction mixture
PT surrounding affinity support, cleaving or eluting chemical molecule from
PT affinity support.
XX
PS Claim 4; Page 70; 81pp; English.
XX
CC The invention comprises a method for providing a labelled target
CC protein/peptide. The method involves contacting a chemical compound with
CC affinity support, removing impurities in the reaction mixture surrounding
CC the affinity support to which the chemical molecule is bound, and
CC cleaving or eluting the molecule from the affinity support to obtain
CC irreversible or reversible affinity tagging residue, labelled target
CC protein or labelled peptide. The method of the invention is useful for

CC labelling a target protein/peptide or high throughput screening assay.
CC The method of the invention is useful for identifying agents that
CC modulate the activity or characteristics of a target protein/peptide -
CC such agents are useful as pharmaceuticals. The present amino acid
CC sequence represents an affinity tag peptide of the invention.

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 24; DB 8; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 10

ADA90172

ID ADA90172 standard; peptide; 5 AA.

XX

AC ADA90172;

XX

DT 20-NOV-2003 (first entry)

XX

DE Anti-Abeta antibody related amino acid sequence SEQ ID NO:287.

XX

KW antibody molecule; antibody; beta-A4 peptide; Abeta4; neuroprotective;
KW nootropic; antiparkinsonian; gene therapy; amyloidogenesis;
KW amyloid-plaque formation; beta-amyloid plaque; immunisation; dementia;
KW Alzheimer's disease; motor neuropathy; Down's syndrome;
KW Creutzfeldt Jacob disease; hereditary cerebral haemorrhage; amyloidosis;
KW Parkinson's disease; HIV-related dementia; amyotrophic lateral sclerosis;
KW neuronal disorder; aging.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO2003070760-A2.

XX

PD 28-AUG-2003.

XX

PF 20-FEB-2003; 2003WO-EP001759.

XX

PR 20-FEB-2002; 2002EP-00003844.

XX

PA (HOFF) HOFFMANN LA ROCHE & CO AG F.

PA (MORP-) MORPHOSYS AG.

XX

PI Bardroff M, Bohrmann B, Brockhaus M, Huber W, Kretzschmar T;

PI Loehning C, Loetscher H, Nordstedt C, Rothe C;

XX

DR WPI; 2003-663848/62.

XX

PT New antibody molecule capable of specifically recognizing two regions of
PT the beta-A4 peptide, useful for diagnosing, preventing or treating
PT diseases associated with amyloidogenesis or amyloid-plaque formation

PT (e.g. dementia).

XX

PS Disclosure; Page 265; 312pp; English.

XX

CC The present invention describes an antibody molecule (I) capable of
CC specifically recognising two regions of the beta-A4 peptide/Abeta4. The
CC first region comprises the amino acid sequence Ala-Glu-Phe-Arg-His-Asp-
CC Ser-Gly-Tyr ADA89886 or its fragment, and the second region comprises the
CC amino acid sequence Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-
CC Gly ADA89887 or its fragment. Also described: (1) a nucleic acid molecule
CC encoding (I); (2) a vector comprising the nucleic acid of (1); (3) a host
CC cell comprising the vector of (2); (4) preparing (I), comprising
culturing the host cell of (3) under conditions that allow synthesis of
CC (I) and recovering (I) from the culture; (5) a composition comprising (I)
CC or an antibody molecule produced by method (4); (6) a kit comprising (I),
CC nucleic acid of (1), vector of (2) or host cell of (3); (7) optimising
CC (I); (8) testing the resulting Fab optimisation library by panning
against Abeta/Abeta4; (9) identifying optimised clones; (10) expressing
CC of selected, optimised clones; (11) preparing a pharmaceutical
CC composition, comprising optimisation of (I), and formulating the
CC optimised antibody/antibody molecule with a carrier; and (12) a
CC pharmaceutical composition prepared by method (8). (I) has
CC neuroprotective, nootropic and antiparkinsonian activities, and can be
used in gene therapy. The antibody molecule (I), nucleic acid molecule,
vector or host is useful in preparing a pharmaceutical composition for
the prevention and/or treatment of a disease associated with
CC amyloidogenesis and/or amyloid-plaque formation. The antibody molecule
CC may also be used in preparing a diagnostic composition for the detection
CC of the disease mentioned above. The antibody is used for the
CC disintegration of beta-amyloid plaques or for passive immunisation
CC against beta-amyloid plaque formation. In particular, the disease is
CC dementia, Alzheimer's disease, motor neuropathy, Down's syndrome,
CC Creutzfeldt Jacob disease, hereditary cerebral haemorrhage with
CC amyloidosis Dutch type, Parkinson's disease, HIV-related dementia,
CC amyotrophic lateral sclerosis or neuronal disorders related to aging. The
CC present sequence is used in the exemplification of the present invention.
XX

SQ Sequence 5 AA;

Query Match 100.0%; Score 24; DB 6; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4

||||

Db 1 EFRH 4

RESULT 11

ADJ71378

ID ADJ71378 standard; peptide; 5 AA.

XX

AC ADJ71378;

XX

DT 06-MAY-2004 (first entry)

XX

DE N-terminal truncated beta-amyloid peptide, SEQ ID 41.

XX
KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW amyloid precursor protein; APP; Alzheimer's disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Pyroglutamic acid"
XX
PN WO2004013172-A2.
XX
PD 12-FEB-2004.
XX
PF 18-JUL-2003; 2003WO-EP007833.
XX
PR 24-JUL-2002; 2002EP-00447147.
PR 06-AUG-2002; 2002US-0401497P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Delacourte A, Sergeant N;
XX
DR WPI; 2004-180423/17.
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a
PT prophylactic vaccine or a therapeutic for preventing or treating a
PT disease associated with beta-amyloid formation and/or aggregation, e.g.
PT Alzheimer's disease.

XX
PS Claim 4; Page 62; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-
CC amyloid peptide variant or beta-amyloid N-terminal fragment, or N-
CC terminal amyloid precursor protein (APP) soluble fragment or C-terminal
CC fragment. The beta-amyloid or APP preparations are useful for
CC manufacturing a prophylactic vaccine or a therapeutic, or as a
CC prophylactic vaccine for the prevention, or as a therapeutic for the
CC treatment of a disease associated with beta-amyloid formation and/or
CC aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 12
ADJ71365
ID ADJ71365 standard; peptide; 5 AA.
XX
AC ADJ71365;

XX
DT 06-MAY-2004 (first entry)
XX
DE N-terminal truncated beta-amyloid peptide, SEQ ID 28.
XX
KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW amyloid precursor protein; APP; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN WO2004013172-A2.
XX
PD 12-FEB-2004.
XX
PF 18-JUL-2003; 2003WO-EP007833.
XX
PR 24-JUL-2002; 2002EP-00447147.
PR 06-AUG-2002; 2002US-0401497P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Delacourte A, Sergeant N;
XX
DR WPI; 2004-180423/17.
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a prophylactic vaccine or a therapeutic for preventing or treating a disease associated with beta-amyloid formation and/or aggregation, e.g. Alzheimer's disease.
XX
PS Claim 4; Page 61; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-amyloid peptide variant or beta-amyloid N-terminal fragment, or N-terminal amyloid precursor protein (APP) soluble fragment or C-terminal fragment. The beta-amyloid or APP preparations are useful for manufacturing a prophylactic vaccine or a therapeutic, or as a prophylactic vaccine for the prevention, or as a therapeutic for the treatment of a disease associated with beta-amyloid formation and/or aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 13
ADJ71352
ID ADJ71352 standard; peptide; 5 AA.
XX
AC ADJ71352;

XX
DT 06-MAY-2004 (first entry)
XX
DE N-terminal truncated beta-amyloid peptide, SEQ ID 15.
XX
KW Nootropic; Neuroprotective; Vaccine; beta Amyloid;
KW amyloid precursor protein; APP; Alzheimer's disease.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "Optionally methylated"
XX
PN WO2004013172-A2.
XX
PD 12-FEB-2004.
XX
PF 18-JUL-2003; 2003WO-EP007833.
XX
PR 24-JUL-2002; 2002EP-00447147.
PR 06-AUG-2002; 2002US-0401497P.
XX
PA (INNO-) INNOGENETICS NV.
XX
PI Delacourte A, Sergeant N;
XX
DR WPI; 2004-180423/17.
XX
PT New beta-amyloid or amyloid precursor protein preparation, useful as a prophylactic vaccine or a therapeutic for preventing or treating a disease associated with beta-amyloid formation and/or aggregation, e.g. Alzheimer's disease.
XX
PS Claim 4; Page 61; 104pp; English.
XX
CC The present invention relates to preparations (I) comprising a beta-amyloid peptide variant or beta-amyloid N-terminal fragment, or N-terminal amyloid precursor protein (APP) soluble fragment or C-terminal fragment. The beta-amyloid or APP preparations are useful for manufacturing a prophylactic vaccine or a therapeutic, or as a prophylactic vaccine for the prevention, or as a therapeutic for the treatment of a disease associated with beta-amyloid formation and/or aggregation, such as Alzheimer's disease.
XX
SQ Sequence 5 AA;

Query Match 100.0%; Score 24; DB 8; Length 5;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
 ||||
Db 2 EFRH 5

RESULT 14

AAW70868

ID AAW70868 standard; peptide; 6 AA.

XX

AC AAW70868;

XX

DT 04-FEB-1999 (first entry)

XX

DE Beta-amyloid peptide to create a monoclonal antibody.

XX

KW Beta-amyloid precursor protein; beta-APP; beta-amyloid peptide; antibody;
KW amyloid deposit; Alzheimer's disease.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9844955-A1.

XX

PD 15-OCT-1998.

XX

PF 09-APR-1998; 98WO-US006900.

XX

PR 09-APR-1997; 97US-0041850P.

XX

PA (MIND-) MINDSET LTD.

PA (MCIN/) MCINNIS P A.

XX

PI Chain DG;

XX

DR WPI; 1998-594476/50.

XX

PT Preventing or inhibiting progression of Alzheimer's Disease - comprises
PT use of recombinant DNA encoding an antibody specific for the N- or C-
PT terminus of an amyloid-beta peptide.

XX

PS Example 1; Page 47; 58pp; English.

XX

CC The present sequence represents a peptide derived from beta-amyloid
CC precursor protein (beta-APP, see AAW70863). The peptide is a beta-amyloid
CC peptide and is used to produce a monoclonal antibody. The specification
CC describes a method for prevention or inhibition of progression of
CC Alzheimer's disease. The method comprises administering a composition
CC comprising a recombinant DNA molecule containing a gene encoding a
CC recombinant antibody end-specific for the N-terminus or the C-terminus of
CC an amyloid-beta peptide, operably linked to a promoter which is expressed
CC in the central nervous system. The recombinant antibody molecules prevent
CC the accumulation of beta-amyloid peptides in the extracellular space,
CC interstitial fluid and cerebrospinal fluid and the aggregation of such
CC peptides into amyloid deposits in the brain. They also inhibit the
CC progression of Alzheimer's disease by inhibiting the interaction of beta-
CC amyloid peptides mediating Alzheimer's disease induced neurotoxicity and
CC inhibiting the Alzheimer's disease induced complement activation and
CC cytokine release involved in the inflammatory process

XX

SQ Sequence 6 AA;

Query Match 100.0%; Score 24; DB 2; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

RESULT 15

AAB47109

ID AAB47109 standard; peptide; 6 AA.

XX

AC AAB47109;

XX

DT 04-JUN-2001 (first entry)

XX

DE Epitope #1 used in treatment of plaque forming disease.

XX

KW Human; prion protein; plaque forming disease; display vehicle; kuru;
KW aggregating protein; amyloid plaque; brain; early onset; senility;
KW Alzheimer's disease; late onset; pre-symptomatic; SAA amyloidosis;
KW hereditary Icelandic syndrome; multiple myeloma; scrapie; BSE; CJD;
KW bovine spongiform encephalopathy; Creutzfeldt-Jakob Disease; FFI;
KW Gerstmann-Streussler-Sheinker Disease; GSS; fatal familial insomnia.

XX

OS Synthetic.

XX

PN WO200118169-A2.

XX

PD 15-MAR-2001.

XX

PF 31-AUG-2000; 2000WO-IL000518.

XX

PR 03-SEP-1999; 99US-0152417P.

PR 29-DEC-1999; 99US-00473653.

PR 31-JUL-2000; 2000US-00629971.

XX

PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.

XX

PI Solomon B, Frenkel D, Hanan E;

XX

DR WPI; 2001-244564/25.

XX

PT Treating amyloidgenic disease such as Alzheimer's disease, BSE or CJD
PT comprises presentation of plaque derived antigens or epitopes on a
PT display vehicle, and introducing the vehicle into the recipient.

XX

PS Example; Page 50; 120pp; English.

XX

CC This peptide is based on the N-terminal fragment of beta-amyloid peptide
CC (beta-AP) and was fused to the minor coat protein of fd phage. This
CC peptide may be used in the method of the invention. The invention
CC provides an agent for treating a plaque forming disease. The polypeptide
CC is displayed on a display vehicle and is capable of eliciting antibodies
CC capable of disaggregating the aggregating protein and/or of preventing
CC aggregation of the aggregating protein. This reduces formation of amyloid
CC plaques in the brain of victims of plaque forming diseases, e.g. early
CC onset Alzheimer's disease, late onset Alzheimer's disease, pre-

CC symptomatic Alzheimer's disease, SAA amyloidosis, hereditary Icelandic
CC syndrome, senility, multiple myeloma, scrapie, bovine spongiform
CC encephalopathy (BSE), kuru, Creutzfeldt-Jakob Disease (CJD), Gerstmann-
CC Streussler-Sheinker Disease (GSS) and fatal familial insomnia (FFI)

XX

SQ Sequence 6 AA;

Query Match 100.0%; Score 24; DB 4; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

Search completed: November 19, 2004, 16:54:07
Job time : 21.3191 secs

GenCore version 5.1.6.
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 19, 2004, 16:39:17 ; Search time 4.68085 Seconds
(without alignments)
56.672 Million cell updates/sec

Title: US-09-830-954A-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued_Patents_AA:*

1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*

2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*

6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

§

Result No.	Score	Query				Description
		Match	Length	DB	ID	
1	24	100.0	4	4	US-09-579-012-24	Sequence 24, Appl
2	24	100.0	7	4	US-09-579-012-25	Sequence 25, Appl
3	24	100.0	10	1	US-08-371-930-12	Sequence 12, Appl
4	24	100.0	10	4	US-09-724-961-5	Sequence 5, Appl
5	24	100.0	10	4	US-09-724-961-6	Sequence 6, Appl
6	24	100.0	10	4	US-09-724-961-7	Sequence 7, Appl
7	24	100.0	10	4	US-09-724-961-8	Sequence 8, Appl
8	24	100.0	10	4	US-09-724-961-9	Sequence 9, Appl
9	24	100.0	10	4	US-09-724-961-10	Sequence 10, Appl
10	24	100.0	10	4	US-09-724-961-11	Sequence 11, Appl
11	24	100.0	10	4	US-09-580-018-5	Sequence 5, Appl

12	24	100.0	10	4	US-09-580-018-6	Sequence 6, Appli
13	24	100.0	10	4	US-09-580-018-7	Sequence 7, Appli
14	24	100.0	10	4	US-09-580-018-8	Sequence 8, Appli
15	24	100.0	10	4	US-09-580-018-9	Sequence 9, Appli
16	24	100.0	10	4	US-09-580-018-10	Sequence 10, Appli
17	24	100.0	10	4	US-09-580-018-11	Sequence 11, Appli
18	24	100.0	10	4	US-09-724-551-5	Sequence 5, Appli
19	24	100.0	10	4	US-09-724-551-6	Sequence 6, Appli
20	24	100.0	10	4	US-09-724-551-7	Sequence 7, Appli
21	24	100.0	10	4	US-09-724-551-8	Sequence 8, Appli
22	24	100.0	10	4	US-09-724-551-9	Sequence 9, Appli
23	24	100.0	10	4	US-09-724-551-10	Sequence 10, Appli
24	24	100.0	10	4	US-09-724-551-11	Sequence 11, Appli
25	24	100.0	10	5	PCT-US94-01712-12	Sequence 12, Appli
26	24	100.0	11	1	US-08-352-179-23	Sequence 23, Appli
27	24	100.0	11	3	US-09-264-709A-6	Sequence 6, Appli
28	24	100.0	12	5	PCT-US94-07043A-2	Sequence 2, Appli
29	24	100.0	13	4	US-09-723-384-2	Sequence 2, Appli
30	24	100.0	13	4	US-09-724-961-72	Sequence 72, Appli
31	24	100.0	13	4	US-09-724-552-2	Sequence 2, Appli
32	24	100.0	13	4	US-09-580-018-72	Sequence 72, Appli
33	24	100.0	13	4	US-09-723-927-2	Sequence 2, Appli
34	24	100.0	13	4	US-09-724-489-2	Sequence 2, Appli
35	24	100.0	13	4	US-09-724-477-2	Sequence 2, Appli
36	24	100.0	13	4	US-09-723-762-2	Sequence 2, Appli
37	24	100.0	13	4	US-09-201-430-2	Sequence 2, Appli
38	24	100.0	13	4	US-09-724-551-72	Sequence 72, Appli
39	24	100.0	15	2	US-08-609-090-1	Sequence 1, Appli
40	24	100.0	16	1	US-08-302-808-10	Sequence 10, Appli
41	24	100.0	16	2	US-08-659-984A-20	Sequence 20, Appli
42	24	100.0	16	2	US-08-986-948-10	Sequence 10, Appli
43	24	100.0	16	3	US-08-660-531-20	Sequence 20, Appli
44	24	100.0	16	5	PCT-US94-07043A-1	Sequence 1, Appli
45	24	100.0	17	4	US-09-594-366-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1

US-09-579-012-24

```
; Sequence 24, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and
Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
```

; SEQ ID NO 24
; LENGTH: 4
; TYPE: PRT
; ORGANISM: consensus sequence
US-09-579-012-24

Query Match 100.0%; Score 24; DB 4; Length 4;
Best Local Similarity 100.0%; Pred. No. 3.8e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 1 EFRH 4

RESULT 2
US-09-579-012-25
; Sequence 25, Application US/09579012
; Patent No. 6670195
; GENERAL INFORMATION:
; APPLICANT: Jorge GHISO
; APPLICANT: Ruben VIDAL
; APPLICANT: Blas FRANGIONE
; TITLE OF INVENTION: New Mutant Genes in Familial British Dementia and
Familial Danish
; TITLE OF INVENTION: Dementia
; FILE REFERENCE: 32004-16277
; CURRENT APPLICATION NUMBER: US/09/579,012
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/136238
; PRIOR FILING DATE: 1999-05-26
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 7
; TYPE: PRT
; ORGANISM: epitope
US-09-579-012-25

Query Match 100.0%; Score 24; DB 4; Length 7;
Best Local Similarity 100.0%; Pred. No. 3.8e+05;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 3
US-08-371-930-12
; Sequence 12, Application US/08371930
; Patent No. 5578451
; GENERAL INFORMATION:
; APPLICANT: Nishimoto, Ikuo
; TITLE OF INVENTION: ALZHEIMER'S DISEASE THERAPEUTICS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/371,930
; FILING DATE:
; CLASSIFICATION: 436
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/019,208
; FILING DATE: February 18, 1993
;
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/154001
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
;
; INFORMATION FOR SEQ ID NO: 12:
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10
; TYPE: amino acid
;
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-371-930-12

Query Match 100.0%; Score 24; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
 ||||
Db 3 EFRH 6

RESULT 4
US-09-724-961-5
;
; Sequence 5, Application US/09724961
; Patent No. 6743427
;
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
;
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
;
; FILE REFERENCE: 15270J-004750UC
;
; CURRENT APPLICATION NUMBER: US/09/724,961
;
; CURRENT FILING DATE: 2000-11-28
;
; PRIOR APPLICATION NUMBER: US 09/580,015

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-5

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 7 EFRH 10

RESULT 5
US-09-724-961-6
; Sequence 6, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02

; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-6

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 6 EFRH 9

RESULT 6

US-09-724-961-7

; Sequence 7, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)

US-09-724-961-7

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 5 EFRH 8

RESULT 7

US-09-724-961-8

; Sequence 8, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)

US-09-724-961-8

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 4 EFRH 7

RESULT 8

US-09-724-961-9
; Sequence 9, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-9

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

RESULT 9
US-09-724-961-10
; Sequence 10, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961

; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07
; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-10

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
 ||||
Db 2 EFRH 5

RESULT 10
US-09-724-961-11
; Sequence 11, Application US/09724961
; Patent No. 6743427
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Vasquez, Nicki
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004750UC
; CURRENT APPLICATION NUMBER: US/09/724,961
; CURRENT FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: US 09/580,015
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/201,430
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: WO PCT/US00/14810
; PRIOR FILING DATE: 1998-11-30
; PRIOR APPLICATION NUMBER: US 60/080,970
; PRIOR FILING DATE: 1998-04-07

; PRIOR APPLICATION NUMBER: US 60/067,740
; PRIOR FILING DATE: 1997-12-02
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-724-961-11

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 1 EFRH 4

RESULT 11

US-09-580-018-5

; Sequence 5, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)

US-09-580-018-5

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 7 EFRH 10

RESULT 12

US-09-580-018-6

; Sequence 6, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)

US-09-580-018-6

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 6 EFRH 9

RESULT 13

US-09-580-018-7

; Sequence 7, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-7

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 5 EFRH 8

RESULT 14

US-09-580-018-8

; Sequence 8, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted
; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)

US-09-580-018-8

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 4 EFRH 7

RESULT 15

US-09-580-018-9

; Sequence 9, Application US/09580018
; Patent No. 6761888
; GENERAL INFORMATION:
; APPLICANT: Schenk, Dale B.
; APPLICANT: Bard, Frederique
; APPLICANT: Yednock, Ted

; TITLE OF INVENTION: Prevention and Treatment of Amyloidogenic Disease
; FILE REFERENCE: 15270J-004760US
; CURRENT APPLICATION NUMBER: US/09/580,018
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/322,289
; PRIOR FILING DATE: 1999-05-28
; NUMBER OF SEQ ID NOS: 77
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 10
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:10-mer peptide
; OTHER INFORMATION: from AN1792 sequence (human Abeta42, beta-amyloid
; OTHER INFORMATION: peptide)
US-09-580-018-9

Query Match 100.0%; Score 24; DB 4; Length 10;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

Search completed: November 19, 2004, 17:00:23
Job time : 5.68085 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 19, 2004, 16:35:52 ; Search time 4.08511 Seconds
(without alignments)
94.212 Million cell updates/sec

Title: US-09-830-954A-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_79:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	DB	ID	Description
1	24	100.0	39	2	A48544	neuropeptide F - b
2	24	100.0	42	2	PN0512	beta-amyloid prote
3	24	100.0	52	2	C91112	hypothetical prote
4	24	100.0	57	2	A60045	Alzheimer's diseas
5	24	100.0	57	2	F60045	Alzheimer's diseas
6	24	100.0	57	2	D60045	Alzheimer's diseas
7	24	100.0	57	2	E60045	Alzheimer's diseas
8	24	100.0	57	2	G60045	Alzheimer's diseas
9	24	100.0	57	2	B60045	Alzheimer's diseas
10	24	100.0	57	2	B89981	truncated transpos
11	24	100.0	82	2	PQ0438	Alzheimer's diseas
12	24	100.0	84	2	G96025	hypothetical prote
13	24	100.0	89	2	C82331	hypothetical prote

14	24	100.0	91	2	T16095	hypothetical prote
15	24	100.0	94	2	B86195	hypothetical prote
16	24	100.0	97	1	RCBP22	abc2 protein - pha
17	24	100.0	97	2	H84901	hypothetical prote
18	24	100.0	106	2	G72059	conserved hypothet
19	24	100.0	106	2	D86563	CT466 hypothetical
20	24	100.0	116	2	B89964	truncated transpos
21	24	100.0	123	2	G95878	probable TRm2011-2
22	24	100.0	132	2	JQ0737	RnpA protein - Mic
23	24	100.0	133	2	AH2580	PTS system, IIA co
24	24	100.0	133	2	F97362	PTS enzyme IIAB, m
25	24	100.0	134	2	B86720	conserved hypothet
26	24	100.0	136	2	B56338	phospholipase A2 (
27	24	100.0	136	2	A87681	conserved hypothet
28	24	100.0	139	1	F64502	hypothetical prote
29	24	100.0	141	2	A99796	hypothetical prote
30	24	100.0	141	2	G85662	unknown protein pr
31	24	100.0	141	2	D85605	unknown in ISEc8 [
32	24	100.0	141	2	A99803	hypothetical prote
33	24	100.0	141	2	E85611	unknown protein in
34	24	100.0	143	2	F75475	3-dehydroquinate d
35	24	100.0	145	2	AD2740	3-dehydroquinate d
36	24	100.0	148	2	B69960	3-dehydroquinate d
37	24	100.0	152	2	D75367	hypothetical prote
38	24	100.0	155	2	AC1187	B. subtilis YdCK p
39	24	100.0	155	2	AB1545	B. subtilis YdCK p
40	24	100.0	156	2	T02166	cysteine proteinas
41	24	100.0	162	2	B97521	3-dehydroquinate d
42	24	100.0	166	2	A28127	myosin light chain
43	24	100.0	167	2	T34963	hypothetical prote
44	24	100.0	176	2	H72201	conserved hypothet
45	24	100.0	176	2	D95322	hypothetical prote

ALIGNMENTS

RESULT 1

A48544

neuropeptide F - brown garden snail

C;Species: Helix aspersa (brown garden snail)

C;Date: 19-Nov-1993 #sequence_revision 18-Nov-1994 #text_change 09-Jul-2004

C;Accession: A48544

R;Leung, P.S.; Shaw, C.; Maule, A.G.; Thim, L.; Johnston, C.F.; Irvine, G.B.
Regul. Pept. 41, 71-81, 1992

A;Title: The primary structure of neuropeptide F (NPF) from the garden snail,
Helix aspersa.

A;Reference number: A48544; MUID:93087780; PMID:1472263

A;Accession: A48544

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-39 <LEU>

A;Cross-references: UNIPROT:P41321

A;Experimental source: circumesophageal ganglia

A;Note: sequence extracted from NCBI backbone (NCBIP:120485)

Query Match

100.0%; Score 24; DB 2; Length 39;

Best Local Similarity 100.0%; Pred. No. 22;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 13 EFRH 16

RESULT 2

PN0512

beta-amyloid protein - guinea pig (fragment)

C;Species: Cavia porcellus (guinea pig)

C;Date: 31-Dec-1993 #sequence_revision 31-Dec-1993 #text_change 09-Jul-2004

C;Accession: PN0512

R;Shimohigashi, Y.; Matsumoto, H.; Takano, Y.; Saito, R.; Iwata, T.; Kamiya, H.; Ohno, M.

Biochem. Biophys. Res. Commun. 193, 624-630, 1993

A;Title: Receptor-mediated specific biological activity of a beta-amyloid protein fragment for NK-1 substance p receptors.

A;Reference number: PN0512; MUID:93290653; PMID:7685598

A;Accession: PN0512

A;Molecule type: protein

A;Residues: 1-42 <SHI>

A;Cross-references: UNIPROT:Q7M088

C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology

C;Keywords: alternative splicing; amyloid

Query Match 100.0%; Score 24; DB 2; Length 42;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 3

C91112

hypothetical protein ECs3867 [imported] - Escherichia coli (strain O157:H7, substrain RIMD 0509952)

C;Species: Escherichia coli

C;Date: 18-Jul-2001 #sequence_revision 18-Jul-2001 #text_change 09-Jul-2004

C;Accession: C91112

R;Hayashi, T.; Makino, K.; Ohnishi, M.; Kurokawa, K.; Ishii, K.; Yokoyama, K.; Han, C.G.; Ohtsubo, E.; Nakayama, K.; Murata, T.; Tanaka, M.; Tobe, T.; Iida, T.; Takami, H.; Honda, T.; Sasakawa, C.; Ogasawara, N.; Yasunaga, T.; Kuhara, S.; Shiba, T.; Hattori, M.; Shinagawa, H.

DNA Res. 8, 11-22, 2001

A;Title: Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12.

A;Reference number: A99629; MUID:21156231; PMID:11258796

A;Accession: C91112

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-52 <HAY>

A;Cross-references: UNIPROT:Q8X2N9; GB:BA000007; PIDN:BAB37290.1; PID:g13363339;
GSPDB:GN00154
A;Experimental source: strain O157:H7, substrain RIMD 0509952
C;Genetics:
A;Gene: ECs3867

Query Match 100.0%; Score 24; DB 2; Length 52;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 24 EFRH 27

RESULT 4
A60045
Alzheimer's disease amyloid beta/A4 protein precursor - dog (fragment)
C;Species: Canis lupus familiaris (dog)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995
C;Accession: A60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: A60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56125
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 8 EFRH 11

RESULT 5
F60045
Alzheimer's disease amyloid beta/A4 protein precursor - pig (fragment)
C;Species: Sus scrofa domestica (domestic pig)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 13-Aug-1999
C;Accession: F60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: F60045

A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56127; NID:g1895; PIDN:CAA39592.1; PID:g1896
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 8 EFRH 11

RESULT 6
D60045
Alzheimer's disease amyloid beta/A4 protein precursor - bovine (fragment)
C;Species: Bos primigenius taurus (cattle)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995
C;Accession: D60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: D60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56124
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 8 EFRH 11

RESULT 7
E60045
Alzheimer's disease amyloid beta/A4 protein precursor - sheep (fragment)
C;Species: Ovis sp. (sheep)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995
C;Accession: E60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide
in dog, polar bear and five other mammals by cross-species polymerase chain
reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157

A;Accession: E60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56130
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 8 EFRH 11

RESULT 8
G60045
Alzheimer's disease amyloid beta/A4 protein precursor - guinea pig (fragment)
C;Species: Cavia porcellus (guinea pig)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 28-Jul-1995
C;Accession: G60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: G60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: EMBL:X56126
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 8 EFRH 11

RESULT 9
B60045
Alzheimer's disease amyloid beta/A4 protein precursor - polar bear (fragment)
C;Species: Ursus maritimus (polar bear)
C;Date: 01-Dec-1992 #sequence_revision 01-Dec-1992 #text_change 09-Jul-2004
C;Accession: B60045
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.

A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: B60045
A;Molecule type: mRNA
A;Residues: 1-57 <JOH>
A;Cross-references: UNIPROT:Q29149; EMBL:X56128; NID:g2165; PIDN:CAA39593.1;
PID:g2166
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type
proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; brain

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 8 EFRH 11

RESULT 10
B89981
truncated transposase [imported] - Staphylococcus aureus (strain N315)
C;Species: Staphylococcus aureus
C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 09-Jul-2004
C;Accession: B89981
R;Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oguchi, A.; Aoki, K.; Nagai, Y.; Lian, J.; Ito, T.; Kanamori, M.; Matsumaru, H.; Maruyama, A.; Murakami, H.; Hosoyama, A.; Mizutani-Ui, Y.; Kobayashi, N.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K.; Hirakawa, H.; Kuhara, S.; Goto, S.; Yabuzaki, J.; Kanehisa, M.; Yamashita, A.; Oshima, K.; Furuya, K.; Yoshino, C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K.
Lancet 357, 1225-1240, 2001
A;Title: Whole genome sequencing of meticillin-resistant Staphylococcus aureus.
A;Reference number: A89758; MUID:21311952; PMID:11418146
A;Accession: B89981
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-57 <KUR>
A;Cross-references: UNIPROT:Q99SW5; GB:BA000018; PID:g13701716; PIDN:BAB43009.1;
GSPDB:GN00149
A;Experimental source: strain N315
C;Genetics:
A;Gene: truncated-tnp

Query Match 100.0%; Score 24; DB 2; Length 57;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 30 EFRH 33

RESULT 11
PQ0438
Alzheimer's disease amyloid A4 protein precursor - rabbit (fragment)
C;Species: Oryctolagus cuniculus (domestic rabbit)

C;Date: 30-Sep-1993 #sequence_revision 19-Oct-1995 #text_change 19-Oct-1995
C;Accession: PQ0438; C60045
R;Davidson, J.S.; West, R.L.; Kotikalapudi, P.; Maroun, L.E.
Biochem. Biophys. Res. Commun. 188, 905-911, 1992
A;Title: Sequence and methylation in the beta/A4 region of the rabbit amyloid precursor protein gene.
A;Reference number: PQ0438; MUID:93075180; PMID:1445331
A;Accession: PQ0438
A;Molecule type: DNA
A;Residues: 1-82 <DAV>
A;Cross-references: GB:M83558; GB:M83657
R;Johnstone, E.M.; Chaney, M.O.; Norris, F.H.; Pascual, R.; Little, S.P.
Brain Res. Mol. Brain Res. 10, 299-305, 1991
A;Title: Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis.
A;Reference number: A60045; MUID:92017079; PMID:1656157
A;Accession: C60045
A;Molecule type: mRNA
A;Residues: 12-68 <JOH>
A;Cross-references: EMBL:X56129
C;Superfamily: Alzheimer's disease amyloid beta protein; animal Kunitz-type proteinase inhibitor homology
C;Keywords: alternative splicing; Alzheimer's disease; amyloid; Down's syndrome

Query Match 100.0%; Score 24; DB 2; Length 82;
Best Local Similarity 100.0%; Pred. No. 48;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 19 EFRH 22

RESULT 12
G96025
hypothetical protein SMB20779 [imported] - Sinorhizobium meliloti (strain 1021)
magaplasmid pSymB
C;Species: Sinorhizobium meliloti
C;Date: 24-Aug-2001 #sequence_revision 24-Aug-2001 #text_change 09-Jul-2004
C;Accession: G96025
R;Finan, T.M.; Weidner, S.; Wong, K.; Buhrmester, J.; Chain, P.; Vorholter, F.J.; Hernandez-Lucas, I.; Becker, A.; Cowie, A.; Gouzy, J.; Golding, B.; Puhler, A.
Proc. Natl. Acad. Sci. U.S.A. 98, 9889-9894, 2001
A;Title: The complete sequence of the 1,683-kb pSymB megaplasmid from the N2-fixing endosymbiont Sinorhizobium meliloti.
A;Reference number: A95842; MUID:21396508; PMID:11481431
A;Accession: G96025
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-84 <KUR>
A;Cross-references: UNIPROT:Q92TN7; GB:AL591985; PIDN:CAC49871.1; PID:g15141359; GSPDB:GN00167
A;Experimental source: strain 1021, megaplasmid pSymB
R;Galibert, F.; Finan, T.M.; Long, S.R.; Puhler, A.; Abola, P.; Ampe, F.; Barloy-Hubler, F.; Barnett, M.J.; Becker, A.; Boistard, P.; Bothe, G.; Boutry,

M.; Bowser, L.; Buhrmester, J.; Cadieu, E.; Capela, D.; Chain, P.; Cowie, A.; Davis, R.W.; Dreano, S.; Federspiel, N.A.; Fisher, R.F.; Gloux, S.; Godrie, T.; Goffeau, A.; Golding, B.; Gouzy, J.; Gurjal, M.; Hernandez-Lucas, I.; Hong, A.; Huizar, L.; Hyman, R.W.; Jones, T.

Science 293, 668-672, 2001

A;Authors: Kahn, D.; Kahn, M.L.; Kalman, S.; Keating, D.H.; Kiss, E.; Komp, C.; Lelaure, V.; Masuy, D.; Palm, C.; Peck, M.C.; Pohl, T.M.; Portetelle, D.; Purnelle, B.; Ramsperger, U.; Surzycki, R.; Thebault, P.; Vandebol, M.; Vorholter, F.J.; Weidner, S.; Wells, D.H.; Wong, K.; Yeh, K.C.; Batut, J.

A;Title: The composite genome of the legume symbiont *Sinorhizobium meliloti*.

A;Reference number: A96039; MUID:21368234; PMID:11474104

A;Contents: annotation

C;Genetics:

A;Gene: SMB20779

A;Genome: plasmid

Query Match 100.0%; Score 24; DB 2; Length 84;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4

||||

Db 15 EFRH 18

RESULT 13

C82331

hypothetical protein VC0383 [imported] - *Vibrio cholerae* (strain N16961 serogroup O1)

C;Species: *Vibrio cholerae*

C;Date: 18-Aug-2000 #sequence_revision 20-Aug-2000 #text_change 09-Jul-2004

C;Accession: C82331

R;Heidelberg, J.F.; Eisen, J.A.; Nelson, W.C.; Clayton, R.A.; Gwinn, M.L.; Dodson, R.J.; Haft, D.H.; Hickey, E.K.; Peterson, J.D.; Umayam, L.A.; Gill, S.R.; Nelson, K.E.; Read, T.D.; Tettelin, H.; Richardson, D.; Ermolaeva, M.D.; Vamathevan, J.; Bass, S.; Qin, H.; Dragoi, I.; Sellers, P.; McDonald, L.; Utterback, T.; Fleishmann, R.D.; Nierman, W.C.; White, O.; Salzberg, S.L.; Smith, H.O.; Colwell, R.R.; Mekalanos, J.J.; Venter, J.C.; Fraser, C.M.

Nature 406, 477-483, 2000

A;Title: DNA Sequence of both chromosomes of the cholera pathogen *Vibrio cholerae*.

A;Reference number: A82035; MUID:20406833; PMID:10952301

A;Accession: C82331

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-89 <HEI>

A;Cross-references: UNIPROT:Q9KUX5; GB:AE004126; GB:AE003852; NID:g9654802; PIDN:AAF93556.1; GSPDB:GN00126; TIGR:VC0383

A;Experimental source: serogroup O1; strain N16961; biotype El Tor

C;Genetics:

A;Gene: VC0383

A;Map position: 1

Query Match 100.0%; Score 24; DB 2; Length 89;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
 ||||
Db 45 EFRH 48

RESULT 14

T16095

hypothetical protein F18E9.6 - *Caenorhabditis elegans*

C;Species: *Caenorhabditis elegans*

C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 09-Jul-2004

C;Accession: T16095

R;Leimbach, D.

submitted to the EMBL Data Library, June 1995

A;Description: The sequence of *C. elegans* cosmid F18E9.

A;Reference number: Z18460

A;Accession: T16095

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-91 <LEI>

A;Cross-references: UNIPROT:Q19566; EMBL:U29614; NID:g868285; PID:g868290;

PIDN:AAA68811.1; CESP:F18E9.6

A;Experimental source: strain Bristol N2

C;Genetics:

A;Gene: CESP:F18E9.6

Query Match 100.0%; Score 24; DB 2; Length 91;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
 ||||
Db 86 EFRH 89

RESULT 15

B86195

hypothetical protein [imported] - *Arabidopsis thaliana*

C;Species: *Arabidopsis thaliana* (mouse-ear cress)

C;Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004

C;Accession: B86195

R;Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso, J.; Altaf, H.; Araujo, R.; Bowman, C.L.; Brooks, S.Y.; Buehler, E.; Chan, A.; Chao, Q.; Chen, H.; Cheuk, R.F.; Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; Dunn, P.; Etgu, P.; Feldblyum, T.V.; Feng, J.; Fong, B.; Fujii, C.Y.; Gill, J.E.; Goldsmith, A.D.; Haas, B.; Hansen, N.F.; Hughes, B.; Huizar, L.

Nature 408, 816-820, 2000

A;Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.J.; Koo, H.L.; Kremenetskaia, I.; Kurtz, D.B.; Kwan, A.; Lam, B.; Langin-Hooper, S.; Lee, A.; Lee, J.M.; Lenz, C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziali, A.; Militscher, J.; Miranda, M.; Nguyen, M.; Nierman, W.C.; Osborne, B.I.; Pai, G.; Peterson, J.; Pham, P.K.; Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.

A;Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon, L.J.; Tambunga, G.; Toriumi, M.J.; Town, C.D.; Utterback, T.; van Aken, S.; Vaysberg, M.; Vysotskaia, V.S.; Walker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.

A;Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A;Reference number: A86141; MUID:21016719; PMID:11130712
A;Accession: B86195
A;Status: preliminary
A;Molecule type: DNA
A;Residues: 1-94 <STO>
A;Cross-references: UNIPROT:Q9LNE5; GB:AE005172; NID:g8810463; PIDN:AAF80124.1;
GSPDB:GN00141
C;Genetics:
A;Map position: 1

Query Match 100.0%; Score 24; DB 2; Length 94;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 31 EFRH 34

Search completed: November 19, 2004, 16:59:18
Job time : 6.08511 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 19, 2004, 16:58:33 ; Search time 16.6809 Seconds
(without alignments)
84.918 Million cell updates/sec

Title: US-09-830-954A-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1570615 seqs, 354127592 residues

Total number of hits satisfying chosen parameters: 1570615

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA:
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep:
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:
18: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:
19: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:
20: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:
*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	Query					Description
No.	Score	Match	Length	DB	ID	
1	24	100.0	4	9	US-09-808-037-1	Sequence 1, Appli
2	24	100.0	4	9	US-09-975-932-8	Sequence 8, Appli
3	24	100.0	4	14	US-10-084-380A-8	Sequence 8, Appli
4	24	100.0	4	14	US-10-162-889-1	Sequence 1, Appli
5	24	100.0	4	15	US-10-384-788-1	Sequence 1, Appli
6	24	100.0	4	15	US-10-618-856-1	Sequence 1, Appli
7	24	100.0	6	9	US-09-808-037-7	Sequence 7, Appli
8	24	100.0	6	9	US-09-975-932-6	Sequence 6, Appli
9	24	100.0	6	14	US-10-084-380A-6	Sequence 6, Appli
10	24	100.0	6	14	US-10-162-889-7	Sequence 7, Appli
11	24	100.0	6	15	US-10-384-788-7	Sequence 7, Appli
12	24	100.0	6	15	US-10-618-856-7	Sequence 7, Appli
13	24	100.0	6	16	US-10-622-087-75	Sequence 75, Appli
14	24	100.0	6	16	US-10-622-087-84	Sequence 84, Appli
15	24	100.0	6	16	US-10-622-087-85	Sequence 85, Appli
16	24	100.0	6	16	US-10-622-087-88	Sequence 88, Appli
17	24	100.0	6	16	US-10-622-087-90	Sequence 90, Appli
18	24	100.0	7	9	US-09-867-847-5	Sequence 5, Appli
19	24	100.0	7	14	US-10-337-970-8	Sequence 8, Appli
20	24	100.0	8	9	US-09-975-932-3	Sequence 3, Appli
21	24	100.0	8	14	US-10-084-380A-3	Sequence 3, Appli
22	24	100.0	8	16	US-10-343-389A-23	Sequence 23, Appli
23	24	100.0	9	15	US-10-619-454-16	Sequence 16, Appli
24	24	100.0	9	15	US-10-619-454-33	Sequence 33, Appli
25	24	100.0	9	15	US-10-619-454-39	Sequence 39, Appli
26	24	100.0	9	15	US-10-619-454-44	Sequence 44, Appli
27	24	100.0	9	15	US-10-619-454-49	Sequence 49, Appli
28	24	100.0	9	15	US-10-619-454-54	Sequence 54, Appli
29	24	100.0	9	15	US-10-619-454-63	Sequence 63, Appli
30	24	100.0	9	15	US-10-619-454-68	Sequence 68, Appli
31	24	100.0	9	15	US-10-619-454-74	Sequence 74, Appli
32	24	100.0	9	15	US-10-619-454-75	Sequence 75, Appli
33	24	100.0	9	15	US-10-619-454-79	Sequence 79, Appli
34	24	100.0	9	15	US-10-619-454-81	Sequence 81, Appli
35	24	100.0	9	15	US-10-619-454-85	Sequence 85, Appli
36	24	100.0	9	15	US-10-619-454-97	Sequence 97, Appli
37	24	100.0	9	15	US-10-619-454-100	Sequence 100, App
38	24	100.0	9	15	US-10-619-454-103	Sequence 103, App
39	24	100.0	9	15	US-10-619-454-112	Sequence 112, App
40	24	100.0	9	15	US-10-619-454-114	Sequence 114, App
41	24	100.0	9	15	US-10-619-454-122	Sequence 122, App
42	24	100.0	9	15	US-10-619-454-125	Sequence 125, App
43	24	100.0	9	15	US-10-619-454-136	Sequence 136, App
44	24	100.0	9	15	US-10-619-454-153	Sequence 153, App
45	24	100.0	9	15	US-10-619-454-166	Sequence 166, App

ALIGNMENTS

RESULT 1
 US-09-808-037-1
 ; Sequence 1, Application US/09808037
 ; Patent No. US20020052311A1

; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR
DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON=2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-09-808-037-1

Query Match 100.0%; Score 24; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
| || |
Db 1 EFRH 4

RESULT 2
US-09-975-932-8
; Sequence 8, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Homo sapiens

US-09-975-932-8

Query Match 100.0%; Score 24; DB 9; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 3

US-10-084-380A-8

; Sequence 8, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; APPLICANT: Chain, Daniel G.
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide,
pharmaceutical compositions
; TITLE OF INVENTION: and methods of use thereof
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: pct/us98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 4
; TYPE: PRT
; ORGANISM: human

US-10-084-380A-8

Query Match 100.0%; Score 24; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 4

US-10-162-889-1

; Sequence 1, Application US/10162889
; Publication No. US20030077252A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
; TITLE OF INVENTION: USEFUL IN DIAGNOSING
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES

; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/162,889
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-10-162-889-1

Query Match 100.0%; Score 24; DB 14; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 5

US-10-384-788-1

; Sequence 1, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING
DISEASE
; FILE REFERENCE: SOLOMON=2D.2
; CURRENT APPLICATION NUMBER: US/10/384,788
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 60/371,735
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 09/808,037
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/830,954
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 10/162,889
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/152,417
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; NUMBER OF SEQ ID NOS: 33

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-384-788-1

Query Match 100.0%; Score 24; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 6
US-10-618-856-1
; Sequence 1, Application US/10618856
; Publication No. US20040052766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY
TECHNOLOGY
; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 4
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-1

Query Match 100.0%; Score 24; DB 15; Length 4;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 1 EFRH 4

RESULT 7
US-09-808-037-7
; Sequence 7, Application US/09808037
; Patent No. US20020052311A1

; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR
DIAGNOSIS OF
; TITLE OF INVENTION: NEUROLOGICAL DISEASES AND DISORDERS
; FILE REFERENCE: SOLOMON=2D
; CURRENT APPLICATION NUMBER: US/09/808,037
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-09-808-037-7

Query Match 100.0%; Score 24; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

RESULT 8
US-09-975-932-6
; Sequence 6, Application US/09975932
; Publication No. US20020086847A1
; GENERAL INFORMATION:
; APPLICANT: CHAIN, Daniel G.
; TITLE OF INVENTION: RECOMBINANT ANTIBODIES SPECIFIC FOR BETA-AMYLOID ENDS,
; TITLE OF INVENTION: DNA ENCODING AND METHODS OF USE THEREOF
; FILE REFERENCE: CHAIN1B
; CURRENT APPLICATION NUMBER: US/09/975,932
; CURRENT FILING DATE: 2001-10-15
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: PCT/US98/06900
; PRIOR FILING DATE: 1998-04-09
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens

US-09-975-932-6

Query Match 100.0%; Score 24; DB 9; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 9

US-10-084-380A-6

; Sequence 6, Application US/10084380A
; Publication No. US20030073655A1
; GENERAL INFORMATION:
; APPLICANT: Mindset Biopharmaceutical Inc.
; APPLICANT: Chain, Daniel G.
; TITLE OF INVENTION: specific antibodies to amyloid beta peptide,
pharmaceutical compositions
; TITLE OF INVENTION: and methods of use thereof
; FILE REFERENCE: P-4815-US1
; CURRENT APPLICATION NUMBER: US/10/084,380A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/041,850
; PRIOR FILING DATE: 1997-04-09
; PRIOR APPLICATION NUMBER: 09/402,820
; PRIOR FILING DATE: 1999-10-12
; PRIOR APPLICATION NUMBER: pct/us98/06900
; PRIOR FILING DATE: 1998-04-09
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 6
; TYPE: PRT
; ORGANISM: human

US-10-084-380A-6

Query Match 100.0%; Score 24; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 10

US-10-162-889-7

; Sequence 7, Application US/10162889
; Publication No. US20030077252A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: HANAN, Eilat
; TITLE OF INVENTION: AGENTS AND COMPOSITIONS AND METHODS UTILIZING SAME
; TITLE OF INVENTION: USEFUL IN DIAGNOSING
; TITLE OF INVENTION: AND/OR TREATING OR PREVENTING PLAQUE FORMING DISEASES

; FILE REFERENCE: SOLOMON=2B
; CURRENT APPLICATION NUMBER: US/10/162,889
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US/09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: US 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide

US-10-162-889-7

Query Match 100.0%; Score 24; DB 14; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 11

US-10-384-788-7

; Sequence 7, Application US/10384788
; Publication No. US20040013647A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING A PLAQUE-FORMING DISEASE
; FILE REFERENCE: SOLOMON=2D.2
; CURRENT APPLICATION NUMBER: US/10/384,788
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: 60/371,735
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 09/808,037
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/830,954
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: 10/162,889
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 09/473,653
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/629,971
; PRIOR FILING DATE: 2000-07-31
; PRIOR APPLICATION NUMBER: 60/152,417
; PRIOR FILING DATE: 1999-09-03
; PRIOR APPLICATION NUMBER: PCT/IL00/00518
; PRIOR FILING DATE: 2000-08-31
; NUMBER OF SEQ ID NOS: 33

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-384-788-7

Query Match 100.0%; Score 24; DB 15; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 12
US-10-618-856-7
; Sequence 7, Application US/10618856
; Publication No. US20040052766A1
; GENERAL INFORMATION:
; APPLICANT: SOLOMON, Beka
; APPLICANT: FRENKEL, Dan
; TITLE OF INVENTION: IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY
; FILE REFERENCE: SOLOMON=2A
; CURRENT APPLICATION NUMBER: US/10/618,856
; CURRENT FILING DATE: 2003-07-15
; PRIOR APPLICATION NUMBER: US/09/473,653A
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: US 60/152,417
; PRIOR FILING DATE: 1999-09-03
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic peptide
US-10-618-856-7

Query Match 100.0%; Score 24; DB 15; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 3 EFRH 6

RESULT 13
US-10-622-087-75
; Sequence 75, Application US/10622087
; Publication No. US20040141984A1

; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Homo sapiens

US-10-622-087-75

Query Match 100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
Db 3 EFRH 6

RESULT 14

US-10-622-087-84

; Sequence 84, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84
; LENGTH: 6
; TYPE: PRT
; ORGANISM: homo sapiens

US-10-622-087-84

Query Match 100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

RESULT 15

US-10-622-087-85

; Sequence 85, Application US/10622087
; Publication No. US20040141984A1
; GENERAL INFORMATION:
; APPLICANT: Bachmann, Martin F
; APPLICANT: Tissot, Alain
; APPLICANT: Ortmann, Rainer
; APPLICANT: Luond, Rainer
; APPLICANT: Staufenbiel, Matthias
; APPLICANT: Frey, Peter
; TITLE OF INVENTION: Amyloid Beta 1-6 Antigen Arrays
; FILE REFERENCE: 1700.0350002
; CURRENT APPLICATION NUMBER: US/10/622,087
; CURRENT FILING DATE: 2003-07-18
; PRIOR APPLICATION NUMBER: US 60/396,639
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: US 60/470,432
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85
; LENGTH: 6
; TYPE: PRT
; ORGANISM: Oryctolagus cuniculus

US-10-622-087-85

Query Match 100.0%; Score 24; DB 16; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 3 EFRH 6

Search completed: November 19, 2004, 17:15:18

Job time : 16.6809 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 19, 2004, 16:35:27 ; Search time 21.4468 Seconds
(without alignments)
107.312 Million cell updates/sec

Title: US-09-830-954A-1

Perfect score: 24

Sequence: 1 EFRH 4

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1825181 seqs, 575374646 residues

Total number of hits satisfying chosen parameters: 1825181

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt_02:
1: uniprot_sprot:
2: uniprot_trembl:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

Result No.	Query Score	Match	Length	DB	ID	Description
1	24	100.0	25	2	Q7R843	Q7r843 plasmodium
2	24	100.0	33	2	Q9UC33	Q9uc33 homo sapien
3	24	100.0	35	2	Q8WZ99	Q8wz99 homo sapien
4	24	100.0	38	2	Q8CM52	Q8cm52 staphylococ
5	24	100.0	38	2	Q8CN66	Q8cn66 staphylococ
6	24	100.0	38	2	Q8CNR0	Q8cnr0 staphylococ
7	24	100.0	38	2	Q8CNT8	Q8cnt8 staphylococ
8	24	100.0	38	2	Q8CP00	Q8cp00 staphylococ
9	24	100.0	38	2	Q8CPT7	Q8cpt7 staphylococ
10	24	100.0	38	2	Q8CPX2	Q8cpx2 staphylococ
11	24	100.0	39	1	NPF_HELAS	P41321 helix asper
12	24	100.0	42	2	Q7M088	Q7m088 cavia porce
13	24	100.0	43	2	Q7UT20	Q7ut20 rhodopirell
14	24	100.0	45	2	Q6V7T6	Q6v7t6 burkholderi
15	24	100.0	45	2	Q8CQ63	Q8cq63 staphylococ

16	24	100.0	45	2	AAQ54942	Aaq54942 burkholde
17	24	100.0	48	2	Q8CN63	Q8cn63 staphylococ
18	24	100.0	52	2	Q8X2N9	Q8x2n9 escherichia
19	24	100.0	55	2	Q7UGM8	Q7ugm8 rhodopirell
20	24	100.0	57	1	A4_URSMA	Q29149 ursus marit
21	24	100.0	57	2	Q8DGN4	Q8dgn4 synechococc
22	24	100.0	57	2	Q99SW5	Q99sw5 staphylococ
23	24	100.0	58	1	A4_CANFA	Q28280 canis famil
24	24	100.0	58	1	A4_RABIT	Q28748 oryctolagus
25	24	100.0	58	1	A4_SHEEP	Q28757 ovis aries
26	24	100.0	59	1	A4_BOVIN	Q28053 bos taurus
27	24	100.0	62	2	Q65802	Q65802 bovine vira
28	24	100.0	62	2	Q65804	Q65804 bovine vira
29	24	100.0	62	2	Q65805	Q65805 bovine vira
30	24	100.0	65	2	Q6IIT6	Q6iit6 drosophila
31	24	100.0	66	2	Q84Z36	Q84z36 oryza sativ
32	24	100.0	67	2	Q98LA2	Q98la2 rhizobium l
33	24	100.0	68	2	O14885	O14885 homo sapien
34	24	100.0	69	2	Q98MZ4	Q98mz4 rhizobium l
35	24	100.0	73	2	Q8GX82	Q8gx82 arabidopsis
36	24	100.0	76	2	Q87L89	Q87189 vibrio para
37	24	100.0	76	2	Q8DCK3	Q8dck3 vibrio vuln
38	24	100.0	77	2	Q6LM57	Q6lm57 photobacter
39	24	100.0	77	2	CAG21620	Cag21620 photobact
40	24	100.0	80	2	Q8GR41	Q8gr41 enterococcus
41	24	100.0	80	2	Q7TCW4	Q7tcw4 untyped hum
42	24	100.0	84	2	Q92TN7	Q92tn7 rhizobium m
43	24	100.0	88	2	Q7MHA4	Q7mha4 vibrio vuln
44	24	100.0	89	2	Q9KUX5	Q9kux5 vibrio chol
45	24	100.0	90	2	Q8VZU1	Q8vzul arabidopsis

ALIGNMENTS

RESULT 1

Q7R843

ID Q7R843 PRELIMINARY; PRT; 25 AA.
 AC Q7R843;
 DT 01-MAR-2004 (TrEMBLrel. 26, Created)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
 DE Hypothetical protein (Fragment).
 GN Name=PY07380;
 OS Plasmodium yoelii yoelii.
 OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
 OX NCBI_TaxID=73239;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=17XNL;
 RX PubMed=12368865;
 RA Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Pertea M.,
 RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
 RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
 RA Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,
 RA Cho J.K., Quackenbush J., Sedegah M., Shoaibi A., Cummings L.M.,
 RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,

RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,
RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA Carucci D.J.;
RT "Genome sequence and comparative analysis of the model rodent malaria
parasite Plasmodium yoelii yoelii.";
RL Nature 419:512-519(2002).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DDBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABL01002689; EAA19793.1; -.
KW Hypothetical protein.
FT NON_TER 1 1
SQ SEQUENCE 25 AA; 3303 MW; 1A5AB86BD78F4422 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 10 EFRH 13

RESULT 2
Q9UC33
ID Q9UC33 PRELIMINARY; PRT; 33 AA.
AC Q9UC33;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Beta-amyloid peptide (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE.
RX MEDLINE=93024877; PubMed=1406936;
RA Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D.,
RA Sinha S., Schlossmacher M., Whaley J., Swindlehurst C.;
RT "Isolation and quantification of soluble Alzheimer's beta-peptide from
RT biological fluids.";
RL Nature 359:325-327(1992).
DR GO; GO:0016021; C:integral to membrane; IEA.
DR GO; GO:0005488; F:binding; IEA.
DR InterPro; IPR001255; Beta-APP.
DR Pfam; PF03494; Beta-APP; 1.
DR PRINTS; PRO0204; BETAAMYLOID.
SQ SEQUENCE 33 AA; 3674 MW; B1DFE2F4167ABD0 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||

Db

3 EFRH 6

RESULT 3

Q8WZ99

ID Q8WZ99 PRELIMINARY; PRT; 35 AA.
AC Q8WZ99;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2002 (TrEMBLrel. 20, Last annotation update)
DE Amyloid protein (Fragment).
GN Name=APP;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX PubMed=15201367;
RA Wakutani Y., Watanabe K., Adachi Y., Wada-Isoe K., Urakami K.,
RA Ninomiya H., Saido TC., Hashimoto T., Iwatsubo T., Nakashima K.;
RT "Novel amyloid precursor protein gene missense mutation (D678N) in
RT probable familial Alzheimer's disease.";
RL J. Neurol. Neurosurg. Psychiatr. 75:1039-1042(2004).
DR EMBL; AB066441; BAB71958.2; -.
FT NON_TER 1 1
FT NON_TER 35 35
SQ SEQUENCE 35 AA; 4084 MW; 49D7D17289743B71 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 19 EFRH 22

RESULT 4

Q8CM52

ID Q8CM52 PRELIMINARY; PRT; 38 AA.
AC Q8CM52;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0257;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;

RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016744; AAO03854.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4448 MW; A40B39C53421AD0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 30 EFRH 33

RESULT 5
Q8CN66
ID Q8CN66 PRELIMINARY; PRT; 38 AA.
AC Q8CN66;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE1982;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016750; AAO05623.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4458 MW; 8BDB217272BB9946 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 30 EFRH 33

RESULT 6
Q8CNR0
ID Q8CNR0 PRELIMINARY; PRT; 38 AA.
AC Q8CNR0;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)

DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Truncated transposase.
 GN OrderedLocusNames=SE1539;
 OS Staphylococcus epidermidis.
 OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
 OX NCBI_TaxID=1282;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 12228;
 RX PubMed=12950922;
 RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
 RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
 RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
 RT "Genome-based analysis of virulence genes in a non-biofilm-forming
 RT Staphylococcus epidermidis strain (ATCC 12228).";
 RL Mol. Microbiol. 49:1577-1593(2003).
 DR EMBL; AE016749; AAO05138.1; -.
 KW Complete proteome.
 SQ SEQUENCE 38 AA; 4434 MW; A415C75C6E85FC4B CRC64;

 Query Match 100.0%; Score 24; DB 2; Length 38;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 1 EFRH 4
 ||||
 Db 30 EFRH 33

RESULT 7
 Q8CNT8
 ID Q8CNT8 PRELIMINARY; PRT; 38 AA.
 AC Q8CNT8;
 DT 01-MAR-2003 (TrEMBLrel. 23, Created)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
 DE Truncated transposase.
 GN OrderedLocusNames=SE1454;
 OS Staphylococcus epidermidis.
 OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
 OX NCBI_TaxID=1282;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=ATCC 12228;
 RX PubMed=12950922;
 RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
 RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
 RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
 RT "Genome-based analysis of virulence genes in a non-biofilm-forming
 RT Staphylococcus epidermidis strain (ATCC 12228).";
 RL Mol. Microbiol. 49:1577-1593(2003).
 DR EMBL; AE016748; AAO05053.1; -.
 KW Complete proteome.
 SQ SEQUENCE 38 AA; 4404 MW; FE0B21726435EC91 CRC64;

 Query Match 100.0%; Score 24; DB 2; Length 38;
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;

Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 30 EFRH 33

RESULT 8

Q8CP00

ID Q8CP00 PRELIMINARY; PRT; 38 AA.
AC Q8CP00;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE1319;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016748; AAO04918.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4495 MW; B1D109D5DC4F3B0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 30 EFRH 33

RESULT 9

Q8CPT7

ID Q8CPT7 PRELIMINARY; PRT; 38 AA.
AC Q8CPT7;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0668;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;

RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016746; AA004265.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4534 MW; A40B3F052E90E80E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 30 EFRH 33

RESULT 10
Q8CPX2
ID Q8CPX2 PRELIMINARY; PRT; 38 AA.
AC Q8CPX2;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0590;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016745; AA004187.1; -.
KW Complete proteome.
SQ SEQUENCE 38 AA; 4395 MW; A40B39DF8421AD0E CRC64;

Query Match 100.0%; Score 24; DB 2; Length 38;
Best Local Similarity 100.08%; Pred. No. 1.7e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
|||
Db 30 EFRH 33

RESULT 11
NPF_HELAS

ID NPF_HELAS STANDARD; PRT; 39 AA.
AC P41321;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Neuropeptide F (NPF).
OS Helix aspersa (Brown garden snail).
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;
OC Sigmurethra; Helicoidea; Helicidae; Helix.
OX NCBI_TaxID=6535;
RN [1]
RP SEQUENCE.
RC TISSUE=Circumoesophageal ganglion;
RX MEDLINE=93087780; PubMed=1472263;
RA Leung P.S., Shaw C., Maule A.G., Thim L., Johnston C.F., Irvine G.B.;
RT "The primary structure of neuropeptide F (NPF) from the garden snail,
RT Helix aspersa.";
RL Regul. Pept. 41:71-81(1992).
CC -!- FUNCTION: May have an important physiological role in
CC neuroregulation.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Neuronal somata and fibers.
CC -!- SIMILARITY: Belongs to the NPY family.
DR PIR; A48544; A48544.
DR HSSP; P41967; 1K8V.
DR InterPro; IPR001955; Pancreatic_hormn.
DR Pfam; PF00159; Hormone_3; 1.
DR PROSITE; PS00265; PANCREATIC_HORMONE_1; 1.
DR PROSITE; PS50276; PANCREATIC_HORMONE_2; 1.
KW Amidation; Direct protein sequencing; Neuropeptide.
FT MOD_RES 39 39 Phenylalanine amide.
SQ SEQUENCE 39 AA; 4855 MW; 4B54AA7414CAAE33 CRC64;

Query Match 100.0%; Score 24; DB 1; Length 39;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 13 EFRH 16

RESULT 12

Q7M088

ID Q7M088 PRELIMINARY; PRT; 42 AA.
AC Q7M088;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Beta-amyloid protein (Fragment).
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE.
RX MEDLINE=93290653; PubMed=7685598;

RA Shimohigashi Y., Matsumoto H., Takano Y., Saito R., Iwata T.,
 RA Kamiya H., Ohno M.;
 RT "Receptor-mediated specific biological activity of a beta-amyloid
 protein fragment for NK-1 substance p receptors.";
 RL Biochem. Biophys. Res. Commun. 193:624-630(1993).
 DR PIR; PN0512; PN0512.
 DR GO; GO:0016021; C:integral to membrane; IEA.
 DR GO; GO:0005488; F:binding; IEA.
 DR InterPro; IPR001255; Beta-APP.
 DR Pfam; PF03494; Beta-APP; 1.
 DR PRINTS; PR00204; BETAAMYLOID.
 FT NON_TER 1 1
 FT NON_TER 42 42
 SQ SEQUENCE 42 AA; 4514 MW; 3AC85563D7858C37 CRC64;

 Query Match 100.0%; Score 24; DB 2; Length 42;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 1 EFRH 4
 ||||
 Db 3 EFRH 6

RESULT 13
 Q7UT20
 ID Q7UT20 PRELIMINARY; PRT; 43 AA.
 AC Q7UT20;
 DT 01-OCT-2003 (TrEMBLrel. 25, Created)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DE Hypothetical protein.
 GN OrderedLocusNames=RB4166;
 OS Rhodopirellula baltica.
 OC Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;
 OC Planctomycetaceae; Pirellula.
 OX NCBI_TaxID=117;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=1;
 RX MEDLINE=22735913; PubMed=12835416;
 RA Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardot T.,
 RA Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,
 RA Schlesner H., Amann R., Reinhardt R.;
 RT "Complete genome sequence of the marine planctomycete Pirellula sp.
 RT strain 1.";
 RL Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303(2003).
 DR EMBL; BX294140; CAD73621.1; -.
 KW Complete proteome; Hypothetical protein.
 SQ SEQUENCE 43 AA; 5428 MW; 3106E49E67D19882 CRC64;

 Query Match 100.0%; Score 24; DB 2; Length 43;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 1 EFRH 4
 ||||

Db 19 EFRH 22

RESULT 14

Q6V7T6

ID Q6V7T6 PRELIMINARY; PRT; 45 AA.
AC Q6V7T6;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Gp6.
OS Burkholderia cepacia phage Bcep22.
OC Viruses; dsDNA viruses, no RNA stage; Caudovirales; Podoviridae.
OX NCBI_TaxID=242527;
RN [1]
RP SEQUENCE FROM N.A.
RA Summer E.J., Cordova M., Parkinson B.C., Fuller A.C., Kitsopoulos K.,
RA Parks B., Rambo L., Rothwell S., Mebane L.M., Carlile T.M., No E.G.,
RA Gonzalez C.M., Young R.F.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
DR EMBL; AY349011; AAQ54942.1; -.
SQ SEQUENCE 45 AA; 5701 MW; 8C2B468B47A94BF9 CRC64;

Query Match 100.0%; Score 24; DB 2; Length 45;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EFRH 4
||||
Db 7 EFRH 10

RESULT 15

Q8CQ63

ID Q8CQ63 PRELIMINARY; PRT; 45 AA.
AC Q8CQ63;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Truncated transposase.
GN OrderedLocusNames=SE0355;
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 12228;
RX PubMed=12950922;
RA Zhang Y.-Q., Ren S.-X., Li H.-L., Wang Y.-X., Fu G., Yang J.,
RA Qin Z.-Q., Miao Y.-G., Wang W.-Y., Chen R.-S., Shen Y., Chen Z.,
RA Yuan Z.-H., Zhao G.-P., Qu D., Danchin A., Wen Y.-M.;
RT "Genome-based analysis of virulence genes in a non-biofilm-forming
RT Staphylococcus epidermidis strain (ATCC 12228).";
RL Mol. Microbiol. 49:1577-1593(2003).
DR EMBL; AE016745; AAO03952.1; -.
KW Complete proteome.
SQ SEQUENCE 45 AA; 5238 MW; 7E3C1EB6774709DB CRC64;

Query Match 100.0%; Score 24; DB 2; Length 45;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EFRH 4
||||
Db 37 EFRH 40

Search completed: November 19, 2004, 16:58:25
Job time : 24.4468 secs